Wiley Matthew T. sold $113K of DFTX

Wiley Matthew T. (Chief Commercial Officer) sold 3,097 shares of Definium Therapeutics, Inc. (DFTX) at $36.57 ($0.11M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wiley Matthew T.
Published Sep 30, 2026, 1:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 1:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFTX
Bearish
medium confidence
Mentioned
$DFTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXBearishLow
01

Why it matters

Provides a concrete data point on insider activity for DFTX, useful for short‑term traders.

02

Market read

Insider sale of modest size may cause slight negative sentiment in DFTX and comparable biotech stocks.

03

What to watch

The sale was pre‑arranged under a 10b5‑1 plan, reducing signaling strength.

Relevance 3/10Novelty 3/10Timing: post‑market filing on 2026‑09‑29

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$DFTXBearishMedium confidence
Context

Chief Commercial Officer sold 3,097 shares for $113,257 via a 10b5‑1 plan, reducing his stake to 359,036 shares.

Expected impact

likely downward pressure as investors price in insider sell

Evidence & confidence

C‑level insider sold over $100k of stock; such sales often trigger modest negative sentiment in small‑cap biotech.

Market effects

May raise caution for other biotech stocks with recent insider sales.

Limited to US biotech sector.

Minimal.

Counterpoint

Insider may have needed liquidity; sale does not reflect company fundamentals.

Key entities

  • Definium Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker DFTX.

  • Wiley Matthew T.

    Chief Commercial Officer of Definium Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFTXHighAI 8/10

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXMedAI 8/10

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT